MedTrace Logo

QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer

NCT01796782 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-02-22

No results posted yet for this study

Summary

Primary End Point:

\- To compare the overall survival (OS) using QYHJ Granules or Xeloda as the second therapy in patients with metastatic pancreatic cancer.

Secondary End Points:

* Compare clinical efficacy by other measures including PFS,tumor response,and changes in quality of life (QOL) between these two groups.
* Examine the feasibility and assess the side effects of treatment using QYHJ Granules in patients with metastatic pancreatic cancer.

Conditions

Interventions

DRUG

Xeloda

Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles

DRUG

QYHJ Granules

1-4 bags bid , days 1-42, every 6 weeks

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • zhen Chen, M.D. · Fudan University

  • lu ming Liu, M.D. · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-08-31
Completion
2015-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01796782 on ClinicalTrials.gov